Diffusion Pharmaceuticals has filed a patent for a novel method of treating viral or bacterial induced respiratory disease with hypoxemia. The method involves administering a diffusion enhancing compound to the patient. GlobalData’s report on Diffusion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Diffusion Pharmaceuticals, peptide pharmacophores was a key innovation area identified from patents. Diffusion Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of viral or bacterial respiratory disease with hypoxemia
A recently filed patent (Publication Number: US20230181509A1) describes a method for treating respiratory diseases with hypoxemia caused by viral or bacterial infections. The method involves administering a diffusion enhancing compound to the patient. The patent also covers the prophylaxis and treatment of hypoxemia, acute respiratory distress syndrome, and multiple organ failure associated with these respiratory diseases.
The claims in the patent specify various respiratory diseases that can be treated using this method, including influenza, coronavirus infections (including COVID-19), and bacterial or viral pneumonia. The diffusion enhancing compound mentioned in the claims is a bipolar trans carotenoid salt (TSC), which can be formulated with a cyclodextrin, such as gamma-cyclodextrin.
The patent also provides instructions for administering the diffusion enhancing compound. It can be given intravenously (IV) or intramuscularly (IM) at a dose ranging from 0.2 to 2 mg/kg or 0.25 to 1.5 mg/kg, depending on the specific application.
Additionally, the patent includes a kit comprising a container with the diffusion enhancing compound and instructions for its use. The kit is designed for treating patients with viral or bacterial induced respiratory diseases, with the recommended dose of the compound ranging from 0.05 to 2.5 mg/kg.
In summary, the patent outlines a method for treating respiratory diseases with hypoxemia caused by viral or bacterial infections. The method involves administering a diffusion enhancing compound, specifically a bipolar trans carotenoid salt (TSC), to the patient. The patent covers various respiratory diseases, including influenza, coronavirus infections (including COVID-19), and bacterial or viral pneumonia. The compound can be given intravenously or intramuscularly at specific doses. The patent also includes a kit with the compound and instructions for its use.
To know more about GlobalData’s detailed insights on Diffusion Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
